{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T10:56:48Z","timestamp":1753181808401},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1016\/j.ygyno.2007.11.017","type":"journal-article","created":{"date-parts":[[2008,1,14]],"date-time":"2008-01-14T07:20:02Z","timestamp":1200295202000},"page":"500-504","source":"Crossref","is-referenced-by-count":7,"title":["Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study"],"prefix":"10.1016","volume":"108","author":[{"given":"Howard","family":"Hochster","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas T.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janice M.","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Day","family":"Hills","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Sorich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juliet","family":"Escalon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Percy","family":"Ivy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonard","family":"Liebes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franco","family":"Muggia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ygyno.2007.11.017_bib1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1093\/jnci\/88.11.734","article-title":"Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines","volume":"88","author":"Kaufmann","year":"1996","journal-title":"J Natl Cancer Inst vol"},{"issue":"1","key":"10.1016\/j.ygyno.2007.11.017_bib2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/annonc\/mdh025","article-title":"International Topotecan Study Group. Long-term survival in phase III, randomized study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma","volume":"15","author":"ten Bokkel Huinink","year":"2004","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ygyno.2007.11.017_bib3","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1200\/JCO.1996.14.12.3056","article-title":"Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study","volume":"14","author":"Creemers","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.11.017_bib4","first-page":"1245","article-title":"Effect of prolonged topotecan infusion on topoisomerase-1 levels: a phase I and pharmacodynamic study","volume":"8","author":"Hochster","year":"1997","journal-title":"Clin Can Res"},{"issue":"8","key":"10.1016\/j.ygyno.2007.11.017_bib5","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1200\/JCO.1999.17.8.2553","article-title":"Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy","volume":"17","author":"Hochster","year":"1999","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2007.11.017_bib6","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.ygyno.2005.08.059","article-title":"Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: an NYGOG and ECOG study","volume":"100","author":"Hochster","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"16","key":"10.1016\/j.ygyno.2007.11.017_bib7","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2007.11.017_bib8","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1200\/JCO.1996.14.12.3074","article-title":"Sequences of topotecan and cisplatin: phase I pharmacologic and in vitro studies to examine sequence dependence","volume":"14","author":"Rowinsky","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.11.017_bib9","unstructured":"Woynarowski JM, Chapman W, Napier C, et al. Mechanisms of action of oxaliplatin: oxaliplatin-induced lesions in cellular DNA. An Antonio (TX): Institute for Drug Development Report; 1997 Jan. Research Report."},{"key":"10.1016\/j.ygyno.2007.11.017_bib10","first-page":"1841","article-title":"In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair","volume":"57","author":"Fink","year":"1997","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.ygyno.2007.11.017_bib11","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/S0006-2952(97)81490-6","article-title":"Oxaliplatin, tetaplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institutes Anticancer Drug Screen panel","volume":"52","author":"Rixe","year":"1996","journal-title":"Biochem Pharmocol"},{"issue":"4","key":"10.1016\/j.ygyno.2007.11.017_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0753-3322(89)90003-6","article-title":"Oxalato-platinum or 1-OHP, a third generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum","volume":"43","author":"Mathe","year":"1989","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.ygyno.2007.11.017_bib13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1093\/oxfordjournals.annonc.a010500","article-title":"Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer","volume":"7","author":"Chollet","year":"1996","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2007.11.017_bib14","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1200\/JCO.1992.10.4.513","article-title":"Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population","volume":"10","author":"Markman","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2007.11.017_bib15","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/S0959-8049(97)00122-6","article-title":"Oxaliplatin\/cisplatin (l-OHP\/CDDP) combination in heavily pretreated ovarian cancer","volume":"33","author":"Soulie","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2007.11.017_bib16","article-title":"Multicentric phase II\u2013III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide in the treatment of advanced ovarian cancer (AOC): toxicity efficacy results","volume":"16","author":"Misset","year":"1997","journal-title":"Proceedings of ASCO"},{"key":"10.1016\/j.ygyno.2007.11.017_bib17","article-title":"Platinum adduct removal in relation to schedule-dependent cytotoxicity of topotecan or SN-38 and platinum (II) and (IV) compounds in vitro","volume":"16","author":"Maliepaard","year":"1997","journal-title":"Proc. ASCO"},{"key":"10.1016\/j.ygyno.2007.11.017_bib18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/0731-7085(90)80122-6","article-title":"High performance liquid chromatography analysis of the new anti-tumor drug SK and F 104864-A (NSC 609699) in plasma","volume":"8","author":"Beijnen","year":"1990","journal-title":"J Pharm Biomed Anal"},{"key":"10.1016\/j.ygyno.2007.11.017_bib19","first-page":"545","article-title":"Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan","volume":"4","author":"Liebes","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2007.11.017_bib20","article-title":"Topotecan\u2013oxaliplatin every three weeks: a phase I and pharmacological study","volume":"18","author":"Misset","year":"1999","journal-title":"Prc Am Soc Clin Onc"},{"issue":"14","key":"10.1016\/j.ygyno.2007.11.017_bib21","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ygyno.2007.11.017_bib22","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"Piccart","year":"2000","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ygyno.2007.11.017_bib23","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1002\/cncr.11901","article-title":"Hypersensitivity and idiosyncratic reactions to oxaliplatin","volume":"100","author":"Bhargava","year":"2004","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2007.11.017_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1093\/annonc\/mdf041","article-title":"Topotecan in combination with carboplatin: phase I trial evaluation of two treatment schedules","volume":"13","author":"Simpson","year":"2002","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.ygyno.2007.11.017_bib25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ygyno.2006.03.014","article-title":"Sequence dependence of hematologic toxicity using carboplatin and topotecan for primary therapy of advanced epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group","volume":"103","author":"Bookman","year":"2006","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ygyno.2007.11.017_bib26","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1634\/theoncologist.11-5-529","article-title":"Topotecan continuous infusion: CA-125 responses including patients pretreated with other schedules of topotecan","volume":"11","author":"Muggia","year":"2006","journal-title":"Oncologist"},{"issue":"16","key":"10.1016\/j.ygyno.2007.11.017_bib27","doi-asserted-by":"crossref","first-page":"5912","DOI":"10.1158\/1078-0432.CCR-04-1240","article-title":"Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer","volume":"11","author":"Mirchandani","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.ygyno.2007.11.017_bib28","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0959-8049(02)00232-0","article-title":"Topotecan preceded by oxaliplatin using a 3\u00a0week schedule: a phase I study in advanced cancer patients","volume":"38","author":"Gross-Goupil","year":"2002","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2007.11.017_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s00280-004-0796-z","article-title":"Phase I\/II trial of topotecan given as continuous infusion in combination with oxaliplatin in 5FU pre-treated patients with colorectal cancer","volume":"54","author":"Hutter","year":"2004","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"10.1016\/j.ygyno.2007.11.017_bib30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2006.08.011","article-title":"A phase I trial of oxaliplatin and weekly topotecan in recurrent ovarian cancer","volume":"104","author":"Elkas","year":"2007","journal-title":"Gyn Oncol"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807009298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825807009298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,6]],"date-time":"2019-05-06T17:32:36Z","timestamp":1557163956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825807009298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["S0090825807009298"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2007.11.017","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}